Specificity Protein 1-Mediated Promotion of CXCL12 Advances Endothelial Cell Metabolism and Proliferation in Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) is a rare yet devastating and incurable disease with few treatment options. The underlying mechanisms of PAH appear to involve substantial cellular proliferation and vascular remodeling, causing right ventricular overload and eventual heart failure. Recent evidence suggests a significant seminal role of the pulmonary endothelium in the initiation and promotion of PAH. Our previous work identified elevated reactive oxygen species (ROS)-producing enzyme NADPH oxidase 1 (NOX1) in human pulmonary artery endothelial cells (HPAECs) of PAH patients promoting endothelial cell proliferation in vitro. In this study, we interrogated chemokine CXCL12′s (aka SDF-1) role in EC proliferation under the control of NOX1 and specificity protein 1 (Sp1). We report here that NOX1 can drive hypoxia-induced endothelial CXCL12 expression via the transcription factor Sp1 leading to HPAEC proliferation and migration. Indeed, NOX1 drove hypoxia-induced Sp1 activation, along with an increased capacity of Sp1 to bind cognate promoter regions in the CXCL12 promoter. Sp1 activation induced elevated expression of CXCL12 in hypoxic HPAECs, supporting downstream induction of expression at the CXCL12 promoter via NOX1 activity. Pathological levels of CXCL12 mimicking those reported in human PAH patient serum restored EC proliferation impeded by specific NOX1 inhibitor. The translational relevance of our findings is highlighted by elevated NOX1 activity, Sp1 activation, and CXCL12 expression in explanted lung samples from PAH patients compared to non-PAH controls. Analysis of phosphofructokinase, glucose-6-phosphate dehydrogenase, and glutaminase activity revealed that CXCL12 induces glutamine and glucose metabolism, which are foundational to EC cell proliferation. Indeed, in explanted human PAH lungs, demonstrably higher glutaminase activity was detected compared to healthy controls. Finally, infusion of recombinant CXCL12 into healthy mice amplified pulmonary arterial pressure, right ventricle remodeling, and elevated glucose and glutamine metabolism. Together these data suggest a central role for a novel NOX1-Sp1-CXCL12 pathway in mediating PAH phenotype in the lung endothelium.

[1]  E. Jacinto,et al.  Targeting mTOR and Metabolism in Cancer: Lessons and Innovations , 2019, Cells.

[2]  R. Bryner,et al.  Exercise training prevents the perivascular adipose tissue-induced aortic dysfunction with metabolic syndrome , 2019, Redox biology.

[3]  M. Humbert,et al.  Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. , 2019, Cardiovascular research.

[4]  Daniel N. Meijles,et al.  Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice. , 2019, American journal of physiology. Lung cellular and molecular physiology.

[5]  C. Camacho,et al.  NADPH oxidase 2 inhibitors CPP11G and CPP11H attenuate endothelial cell inflammation & vessel dysfunction and restore mouse hind-limb flow , 2019, Redox biology.

[6]  M. Gladwin,et al.  Nox1/Ref-1-mediated activation of CREB promotes Gremlin1-driven endothelial cell proliferation and migration , 2019, Redox biology.

[7]  M. Boerries,et al.  CXCL12 and MYC control energy metabolism to support adaptive responses after kidney injury , 2018, Nature Communications.

[8]  P. Carmeliet,et al.  Endothelial Cell Metabolism in Health and Disease. , 2017, Trends in cell biology.

[9]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[10]  S. Chan,et al.  Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice , 2017, European Respiratory Review.

[11]  Daniel N. Meijles,et al.  Endothelial Nox1 oxidase assembly in human pulmonary arterial hypertension; driver of Gremlin1-mediated proliferation. , 2017, Clinical science.

[12]  F. Chen,et al.  Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension , 2017, Antioxidants.

[13]  S. Provencher,et al.  The cancer theory of pulmonary arterial hypertension , 2017, Pulmonary circulation.

[14]  J. Wharton,et al.  Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2&agr; , 2016, Circulation.

[15]  Mary E. Ziegler,et al.  mTORC2 mediates CXCL12-induced angiogenesis , 2016, Angiogenesis.

[16]  D. Saul,et al.  CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis , 2016, Leukemia.

[17]  Wei Zhang,et al.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks , 2016, Oncogene.

[18]  Y. Miyagi,et al.  Diverse Mechanisms of Sp1-Dependent Transcriptional Regulation Potentially Involved in the Adaptive Response of Cancer Cells to Oxygen-Deficient Conditions , 2015, Cancers.

[19]  R. Benza,et al.  Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.

[20]  B. Kang,et al.  Targeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension. , 2015, Free radical biology & medicine.

[21]  S. Scala Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment , 2015, Clinical Cancer Research.

[22]  A. Morton,et al.  Elevated Plasma CXCL12α Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension , 2015, PloS one.

[23]  M. Mihailović,et al.  Identification of transcription factors involved in the transcriptional regulation of the CXCL12 gene in rat pancreatic insulinoma Rin-5F cell line. , 2015, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[24]  Guojun Wu,et al.  Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. , 2015, Biochemical and biophysical research communications.

[25]  T. Bancroft,et al.  The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients , 2014, BMC Health Services Research.

[26]  J. Blenis,et al.  The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation , 2014, Current Biology.

[27]  T. Finkel,et al.  Cellular mechanisms and physiological consequences of redox-dependent signalling , 2014, Nature Reviews Molecular Cell Biology.

[28]  E. Michelakis,et al.  The metabolic basis of pulmonary arterial hypertension. , 2014, Cell metabolism.

[29]  M. Gladwin,et al.  Selective Recapitulation of Conserved and Nonconserved Regions of Putative NOXA1 Protein Activation Domain Confers Isoform-specific Inhibition of Nox1 Oxidase and Attenuation of Endothelial Cell Migration* , 2013, The Journal of Biological Chemistry.

[30]  Yuichiro J Suzuki,et al.  Reactive oxygen species and antioxidants in pulmonary hypertension. , 2013, Antioxidants & redox signaling.

[31]  Gregory Stephanopoulos,et al.  The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.

[32]  J. Joseph,et al.  Real-time monitoring of reactive oxygen and nitrogen species in a multiwell plate using the diagnostic marker products of specific probes. , 2013, Methods in enzymology.

[33]  J. Joseph,et al.  Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides. , 2012, Chemical research in toxicology.

[34]  R. Benza,et al.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.

[35]  Jian Ding,et al.  Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis (CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells* , 2012, The Journal of Biological Chemistry.

[36]  J. Belperio,et al.  A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease , 2011, European Respiratory Journal.

[37]  H. Coller,et al.  The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. , 2010, Genes & development.

[38]  N. Voelkel,et al.  Reversible or irreversible remodeling in pulmonary arterial hypertension. , 2010, American journal of respiratory cell and molecular biology.

[39]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[40]  F. Lanner,et al.  Sp1 mediate hypoxia induced ephrinB2 expression via a hypoxia-inducible factor independent mechanism. , 2010, Biochemical and Biophysical Research Communications - BBRC.

[41]  N. Voelkel,et al.  Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation , 2009, Respiratory research.

[42]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[43]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[44]  M. D'Addario,et al.  Role of p38 in stress activation of Sp1. , 2006, Gene.

[45]  F. Arenzana‐Seisdedos,et al.  Functional characterization of SDF-1 proximal promoter. , 2005, Journal of molecular biology.

[46]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[47]  J. Loscalzo,et al.  Glucose-6-phosphate Dehydrogenase Modulates Vascular Endothelial Growth Factor-mediated Angiogenesis* , 2003, Journal of Biological Chemistry.

[48]  R. Neve,et al.  Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons , 2003, The Journal of Neuroscience.

[49]  M. D'Addario,et al.  Interaction of p38 and Sp1 in a Mechanical Force-induced, β1 Integrin-mediated Transcriptional Circuit That Regulates the Actin-binding Protein Filamin-A* , 2002, The Journal of Biological Chemistry.

[50]  J. Pouysségur,et al.  Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases , 2002, The Journal of Biological Chemistry.

[51]  Christine C. Hudson,et al.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.